Clinitech Laboratory Limited
BBSE:CTLLAB32.00
INR
-1.65
(-4.90%)
Clinitech Laboratory Limited
BSE:CTLLAB
(Bombay Stock Exchange)
Recent
price
32.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Clinitech Laboratory Limited is an India-based diagnostic and pathological laboratory service provider headquartered in Navi Mumbai, Maharashtra. Founded in 1993, the company provides diagnostic testing, healthcare screening, and clinical examination services to individual patients, healthcare professionals, hospitals, nursing homes, and corporate institutions. The company operates through comprehensive pathology and diagnostic service lines, offering an extensive portfolio of medical investigation services, which include: routine and specialized clinical biochemistry tests; comprehensive hematology and coagulation profiling; clinical pathology and urinalysis; microbiology, serology, and automated bacterial culture examinations; immunological and endocrine hormone assays; molecular diagnostics and polymerase chain reaction (PCR) testing; histopathology and cytopathology investigations; comprehensive allergy panels; oncology tumor marker screenings; customized preventive healthcare checkup packages; pre-employment medical examinations; occupational health checkups; and home sample collection services. The company conducts its operations across the Mumbai Metropolitan Region and Thane districts in Maharashtra, India, supported by a central laboratory facility, regional diagnostic centers, and a network of patient service centers. In recent developments, Clinitech Laboratory completed its Initial Public Offering (IPO) and listed its equity shares on the BSE SME platform under the ticker CTLLAB, securing fresh capital to finance the establishment of new diagnostic centers and collection points, procure high-throughput automated laboratory diagnostic machinery, upgrade laboratory information systems, and support regional expansion. Additionally, the company transitioned from a private entity to a public limited company and expanded its diagnostic capabilities by introducing advanced molecular biology testing and specialized preventive wellness screening programs.